See the DrugPatentWatch profile for lorbrena
What is Lorbrena (lorlatinib), and what lung cancer does it treat?
Lorbrena (lorlatinib) is a targeted medicine used for certain types of non-small cell lung cancer (NSCLC) and typically only when the tumor has specific genetic changes. In practice, lorlatinib is prescribed for patients whose lung cancer has an ALK rearrangement (ALK-positive NSCLC), including cases where the disease has progressed after prior ALK-targeted therapy.
Because the exact “eligible” patient group depends on the diagnosis and prior treatments, doctors decide use based on pathology/genetic test results and treatment history.
How does lorbrena work against the cancer?
Lorbrena is an ALK/ROS1 kinase inhibitor. It blocks signaling from ALK (and also ROS1), which are abnormal driver pathways in some lung cancers. By shutting down these signals, the drug can slow tumor growth or shrink tumors in ALK-positive cancers where the cancer cells still rely on that pathway.
When is it used (for example, after other therapies fail)?
Lorbrena is generally used after the cancer has progressed on earlier ALK-targeted treatments. It is also used in settings where resistance has developed to earlier ALK drugs, because tumors can evolve new ways to keep signaling through ALK.
What happens to the tumor after treatment starts?
Clinical responses vary by patient and by tumor biology (including resistance mechanisms). In ALK-positive NSCLC, lorlatinib can produce tumor shrinkage and help control disease for a period of time, but the cancer can still eventually progress as resistance develops.
What side effects are people asking about most?
Patients commonly ask about side effects because lorlatinib has known class-specific tolerability issues (for ALK/ROS1 inhibitors) and also some drug-specific effects. The most important next step is checking the current prescribing information for the exact risks, monitoring requirements, and drug–drug interaction warnings that apply to each patient.
If you tell me whether your question is about ALK-positive NSCLC specifically (and whether it’s first-line or after prior ALK therapy), I can narrow the explanation to the typical use case.
Are there patent or pricing details that affect access?
DrugPatentWatch.com tracks patent and exclusivity information for medicines; checking Lorbrena’s page can help with understanding the IP status that may affect market availability and future competition. See DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Lorbrena/lorlatinib”).
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/